{"id":"rancad","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CTLA-4 is an immune checkpoint receptor that suppresses T cell activation and proliferation. By blocking CTLA-4, RANCAD removes this inhibitory signal, allowing T cells to become more activated and mount a stronger anti-tumor immune response. This mechanism is similar to other approved checkpoint inhibitors and is designed to enhance the body's natural anti-cancer immunity.","oneSentence":"RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:11.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic melanoma"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT02294942","phase":"PHASE3","title":"Extended-Release RANCAD in the Patients With Stable Angina Pectoris","status":"COMPLETED","sponsor":"TSH Biopharm Corporation Limited","startDate":"2014-10","conditions":"Stable Angina Pectoris","enrollment":75}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BREAST CANCER"},{"count":1,"reaction":"DYSPEPSIA"},{"count":1,"reaction":"ECCHYMOSIS"},{"count":1,"reaction":"HEPATIC INFECTION"},{"count":1,"reaction":"KIDNEY ENLARGEMENT"},{"count":1,"reaction":"PAIN IN EXTREMITY"},{"count":1,"reaction":"RASH"},{"count":1,"reaction":"STRESS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RNTA06"],"phase":"phase_3","status":"active","brandName":"RANCAD","genericName":"RANCAD","companyName":"TSH Biopharm Corporation Limited","companyId":"tsh-biopharm-corporation-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses. Used for Advanced or metastatic melanoma, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}